Apellis Pharma stock more than doubled as Biogen announced a $5.6 billion acquisition. But for investors looking to jump into APLS shares now, the ship has already sailed.
Apellis Pharma Skyrockets on Biogen Deal. Is It Too Late to Chase APLS Stock?
Apellis Pharma stock more than doubled as Biogen announced a $5.6 billion acquisition. But for investors looking to jump into APLS shares now, the ship has already sailed.